ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.122,25
0,95%
S&P 500
5.064,20
0,91%
US Dollar vs BRL
5,1111
-0,01%
Bitcoin
59.368,29
0,42%
Brent Oil
83,915
0,34%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Tarsus Pharmaceuticals Inc (TARS)

  7. Tarsus Pharmaceuticals Inc (TARS) Notícias

TARS

Tarsus Pharmaceuticals (TARS)

Tarsus Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:TARS
DataHoraFonteTítuloCódigoCompanhia
01/05/202418:00GlobeNewswire Inc.Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024NASDAQ:TARSTarsus Pharmaceuticals Inc
23/04/202409:30GlobeNewswire Inc.Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from PharmakonNASDAQ:TARSTarsus Pharmaceuticals Inc
11/03/202418:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
05/03/202418:30GlobeNewswire Inc.Tarsus to Participate at Upcoming Investor ConferencesNASDAQ:TARSTarsus Pharmaceuticals Inc
05/03/202418:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TARSTarsus Pharmaceuticals Inc
05/03/202410:30GlobeNewswire Inc.Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex BlepharitisNASDAQ:TARSTarsus Pharmaceuticals Inc
01/03/202419:17Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TARSTarsus Pharmaceuticals Inc
01/03/202402:07GlobeNewswire Inc.Tarsus Announces Pricing of $100.0 Million Public OfferingNASDAQ:TARSTarsus Pharmaceuticals Inc
29/02/202418:37GlobeNewswire Inc.Tarsus Announces Proposed $100.0 Million Public OfferingNASDAQ:TARSTarsus Pharmaceuticals Inc
29/02/202418:32Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:TARSTarsus Pharmaceuticals Inc
27/02/202418:22Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TARSTarsus Pharmaceuticals Inc
27/02/202418:02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TARSTarsus Pharmaceuticals Inc
27/02/202408:00GlobeNewswire Inc.Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business AchievementsNASDAQ:TARSTarsus Pharmaceuticals Inc
22/02/202410:00GlobeNewswire Inc.Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme DiseaseNASDAQ:TARSTarsus Pharmaceuticals Inc
20/02/202419:00GlobeNewswire Inc.Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024NASDAQ:TARSTarsus Pharmaceuticals Inc
31/01/202419:00GlobeNewswire Inc.Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks ConferenceNASDAQ:TARSTarsus Pharmaceuticals Inc
22/01/202419:05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TARSTarsus Pharmaceuticals Inc
27/12/202318:23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
11/12/202310:00GlobeNewswire Inc.Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex MitesNASDAQ:TARSTarsus Pharmaceuticals Inc
22/11/202302:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:TARSTarsus Pharmaceuticals Inc
09/11/202318:18Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:TARSTarsus Pharmaceuticals Inc
09/11/202318:05GlobeNewswire Inc.Tarsus Reports Third Quarter 2023 Financial Results and Recent Business AchievementsNASDAQ:TARSTarsus Pharmaceuticals Inc
09/11/202318:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TARSTarsus Pharmaceuticals Inc
01/11/202319:35GlobeNewswire Inc.Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023NASDAQ:TARSTarsus Pharmaceuticals Inc
06/09/202309:00GlobeNewswire Inc.Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex BlepharitisNASDAQ:TARSTarsus Pharmaceuticals Inc
30/08/202317:30GlobeNewswire Inc.Tarsus to Present at Upcoming Investor ConferencesNASDAQ:TARSTarsus Pharmaceuticals Inc
24/08/202310:00GlobeNewswire Inc.Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex BlepharitisNASDAQ:TARSTarsus Pharmaceuticals Inc
10/08/202317:05GlobeNewswire Inc.Tarsus Reports Second Quarter 2023 Financial Results and Recent Business AchievementsNASDAQ:TARSTarsus Pharmaceuticals Inc
01/08/202323:30GlobeNewswire Inc.Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common StockNASDAQ:TARSTarsus Pharmaceuticals Inc
31/07/202317:29GlobeNewswire Inc.Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common StockNASDAQ:TARSTarsus Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:TARS

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
BBDC4
BRADESCO PN
BOV
PRIO3
PETRORIO ON
BOV
GOLL4
GOL PN
BOV
BHIA3
Grupo Casas Bahia ON
BOV
BEES3
BANESTES ON
BOV
COGN3
COGNA ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados